Tweet
The American Urological Association and the American Society for Radiation Oncology (AUA/ASTRO) just issued new guidelines for the treatment of localized prostate cancer.
There are major changes for active surveillance, being the preferred treatment for all low risk cases. Also, AS can now be considered for select favorable intermediate risk men.
There are cautions about the lack of high quality data for focal ablation, and a statement that proton has not been shown to be superior to other radiation choices in outcomes and toxicities. Lots of good information here that patients, especially those deciding treatment, should be aware of.
These new guidelines are the result of studies and discussions of new findings since the last publication five years ago.
https://www.auanet.org/guidelines/gu...yY_04pbG0B8CAw jXKdGDbn7pbIRCuD6HYV2ruF4ywGEVXJc
There are major changes for active surveillance, being the preferred treatment for all low risk cases. Also, AS can now be considered for select favorable intermediate risk men.
There are cautions about the lack of high quality data for focal ablation, and a statement that proton has not been shown to be superior to other radiation choices in outcomes and toxicities. Lots of good information here that patients, especially those deciding treatment, should be aware of.
These new guidelines are the result of studies and discussions of new findings since the last publication five years ago.
https://www.auanet.org/guidelines/gu...yY_04pbG0B8CAw jXKdGDbn7pbIRCuD6HYV2ruF4ywGEVXJc
Comment